(Q38241987)

31 August 2017

title

Role of the MEK inhibitor trametinib in the treatment of metastatic melanoma (English)

1 reference

31 August 2017

Judy W King

1

1 reference

31 August 2017

Paul D Nathan

series ordinal

2

1 reference

31 August 2017

language of work or name

English

0 references

publication date

1 January 2014

1 reference

31 August 2017

1 reference

31 August 2017

volume

10

1 reference

31 August 2017

issue

9

1 reference

31 August 2017

page(s)

1559-1570

1 reference

Management of cutaneous melanoma

31 August 2017

cites work

1 reference

Improved Survival with Ipilimumab in Patients with Metastatic Melanoma

21 January 2018

1 reference

Improved survival with vemurafenib in melanoma with BRAF V600E mutation

21 January 2018

1 reference

Anti-cytotoxic T-lymphocyte antigen-4 antibody: the first in an emerging class of immunomodulatory antibodies for cancer treatment

21 January 2018

1 reference

Single-institution experience with ipilimumab in advanced melanoma patients in the compassionate use setting: lymphocyte count after 2 doses correlates with survival

21 January 2018

1 reference

Autoimmunity and treatment outcome in melanoma

21 January 2018

1 reference

Autoimmunity correlates with tumor regression in patients with metastatic melanoma treated with anti-cytotoxic T-lymphocyte antigen-4.

21 January 2018

1 reference

Prognostic factors related to clinical response in patients with metastatic melanoma treated by CTL-associated antigen-4 blockade

21 January 2018

1 reference

Characterization of AMN107, a selective inhibitor of native and mutant Bcr-Abl.

21 January 2018

1 reference

Integrated NY-ESO-1 antibody and CD8+ T-cell responses correlate with clinical benefit in advanced melanoma patients treated with ipilimumab

21 January 2018

1 reference

CTLA-4 blockade with ipilimumab: long-term follow-up of 177 patients with metastatic melanoma

21 January 2018

1 reference

A prospective phase II trial exploring the association between tumor microenvironment biomarkers and clinical activity of ipilimumab in advanced melanoma.

21 January 2018

1 reference

Constitutive activation of the Ras-Raf signaling pathway in metastatic melanoma is associated with poor prognosis

21 January 2018

1 reference

Distinct sets of genetic alterations in melanoma

21 January 2018

1 reference

Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib

21 January 2018

1 reference

Mutations of the BRAF gene in human cancer

21 January 2018

1 reference

Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial

21 January 2018

1 reference

Widespread potential for growth-factor-driven resistance to anticancer kinase inhibitors.

21 January 2018

1 reference

Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation

21 January 2018

1 reference

Dissecting therapeutic resistance to RAF inhibition in melanoma by tumor genomic profiling

21 January 2018

1 reference

RAF inhibitor resistance is mediated by dimerization of aberrantly spliced BRAF(V600E)

21 January 2018

1 reference

Resistance to selective BRAF inhibition can be mediated by modest upstream pathway activation

21 January 2018

1 reference

Melanoma whole-exome sequencing identifies (V600E)B-RAF amplification-mediated acquired B-RAF inhibitor resistance

21 January 2018

1 reference

Increased cyclin D1 expression can mediate BRAF inhibitor resistance in BRAF V600E-mutated melanomas

21 January 2018

1 reference

PTEN loss confers BRAF inhibitor resistance to melanoma cells through the suppression of BIM expression

21 January 2018

1 reference

COT drives resistance to RAF inhibition through MAP kinase pathway reactivation

21 January 2018

1 reference

Acquired resistance and clonal evolution in melanoma during BRAF inhibitor therapy

21 January 2018

1 reference

Improved survival with MEK inhibition in BRAF-mutated melanoma

21 January 2018

1 reference

Paradoxical oncogenesis--the long-term effects of BRAF inhibition in melanoma

21 January 2018

1 reference

The RAF inhibitor PLX4032 inhibits ERK signaling and tumor cell proliferation in a V600E BRAF-selective manner

21 January 2018

1 reference

RAF inhibitors prime wild-type RAF to activate the MAPK pathway and enhance growth

21 January 2018

1 reference

Kinase-dead BRAF and oncogenic RAS cooperate to drive tumor progression through CRAF

21 January 2018

1 reference

Progression of RAS-mutant leukemia during RAF inhibitor treatment

21 January 2018

1 reference

Atypical melanocytic proliferations and new primary melanomas in patients with advanced melanoma undergoing selective BRAF inhibition

21 January 2018

1 reference

GSK1120212 (JTP-74057) is an inhibitor of MEK activity and activation with favorable pharmacokinetic properties for sustained in vivo pathway inhibition

21 January 2018

1 reference

RDEA119/BAY 869766: a potent, selective, allosteric inhibitor of MEK1/2 for the treatment of cancer

21 January 2018

1 reference

Phase I and pharmacodynamic study of the oral MEK inhibitor CI-1040 in patients with advanced malignancies

21 January 2018

1 reference

Phase I pharmacokinetic and pharmacodynamic study of the oral, small-molecule mitogen-activated protein kinase kinase 1/2 inhibitor AZD6244 (ARRY-142886) in patients with advanced cancers

21 January 2018

1 reference

Safety, pharmacokinetic, pharmacodynamic, and efficacy data for the oral MEK inhibitor trametinib: a phase 1 dose-escalation trial

21 January 2018

1 reference

Dabrafenib in patients with melanoma, untreated brain metastases, and other solid tumours: a phase 1 dose-escalation trial.

21 January 2018

1 reference

Phase II study of the MEK1/MEK2 inhibitor Trametinib in patients with metastatic BRAF-mutant cutaneous melanoma previously treated with or without a BRAF inhibitor

21 January 2018

1 reference

BRAF V600E disrupts AZD6244-induced abrogation of negative feedback pathways between extracellular signal-regulated kinase and Raf proteins

21 January 2018

1 reference

Biological characterization of ARRY-142886 (AZD6244), a potent, highly selective mitogen-activated protein kinase kinase 1/2 inhibitor

21 January 2018

1 reference

The first-in-human study of the hydrogen sulfate (Hyd-sulfate) capsule of the MEK1/2 inhibitor AZD6244 (ARRY-142886): a phase I open-label multicenter trial in patients with advanced cancer

21 January 2018

1 reference

MEK162 for patients with advanced melanoma harbouring NRAS or Val600 BRAF mutations: a non-randomised, open-label phase 2 study

21 January 2018

1 reference

Pharmacodynamic effects and mechanisms of resistance to vemurafenib in patients with metastatic melanoma

21 January 2018

1 reference

MEK1 mutations confer resistance to MEK and B-RAF inhibition

21 January 2018

1 reference

Exome sequencing identifies recurrent somatic MAP2K1 and MAP2K2 mutations in melanoma.

21 January 2018

1 reference

Acquired resistance to BRAF inhibitors mediated by a RAF kinase switch in melanoma can be overcome by cotargeting MEK and IGF-1R/PI3K

21 January 2018

1 reference

Amplification of the driving oncogene, KRAS or BRAF, underpins acquired resistance to MEK1/2 inhibitors in colorectal cancer cells.

21 January 2018

1 reference

Effect of SMURF2 targeting on susceptibility to MEK inhibitors in melanoma

21 January 2018

1 reference

Intrinsic resistance to the MEK1/2 inhibitor AZD6244 (ARRY-142886) is associated with weak ERK1/2 signalling and/or strong PI3K signalling in colorectal cancer cell lines

21 January 2018

1 reference

PI3K pathway activation mediates resistance to MEK inhibitors in KRAS mutant cancers

21 January 2018

1 reference

Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations

21 January 2018

1 reference

Modelling vemurafenib resistance in melanoma reveals a strategy to forestall drug resistance

21 January 2018

1 reference

PD0325901, a mitogen-activated protein kinase kinase inhibitor, produces ocular toxicity in a rabbit animal model of retinal vein occlusion

21 January 2018

1 reference

Disease flare after tyrosine kinase inhibitor discontinuation in patients with EGFR-mutant lung cancer and acquired resistance to erlotinib or gefitinib: implications for clinical trial design.

21 January 2018

1 reference

Nivolumab plus ipilimumab in advanced melanoma

21 January 2018

1 reference

Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced Cancer

21 January 2018

1 reference

Hepatotoxicity with combination of vemurafenib and ipilimumab

21 January 2018

1 reference

An immune-active tumor microenvironment favors clinical response to ipilimumab

21 January 2018

1 reference

21 January 2018

Identifiers

DOI

10.2217/FON.14.89

1 reference

31 August 2017

1 reference